Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

178 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patient with moderately severe or severe symptomatic severe hyponatremia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia

NCT04949139

Hypernatremia

COMPLETED PHASE4

Establishment of an Algorithm for a Clinical Classfication of Hypoosmolar Hyponatremia

NCT00541944

Hyponatremia

COMPLETED

Mortality and Neurologic Outcomes in Rapid vs. Slow Hyponatremia Correction

NCT06675591

Hyponatremia Hospitalisation Mortality +1 more

COMPLETED

Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.

NCT04561531

Hyponatremia Osmotic Demyelination Syndrome

UNKNOWN NA

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

NCT01227512

Hyponatremia Dilutional Hyponatremia Inappropriate ADH Syndrome

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Moderate to severe symptomatic hyponatremia requires prompt treatment with hypertonic saline. The extent and rate of increase in serum sodium (sNa) levels during treatment are critical. Several methods for continuous infusion of hypertonic saline were used to guide rate of fluid administered to achieve the required serum sodium target. As based on static model, they had a bias to over-correction of hyponatremia. Alternative approach to treatment with hypertonic fluid is to use small, fixed boluses to achieve controlled increments in sNa. However, there was no high quality evidence on whether hypertonic saline are best given in continuous infusion (preferred by most) or bolus injection. The aim of present study, a multi-center (Seoul National University Bundang Hospital \[2016.8\~\], Seoul National University Boramae Medical Center \[2016. 9\~\], Hallym University Dongtan Sacred Heart Hospital \[2017.7\~\]), randomized, open labelled, controlled clinical trial, is to investigate efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patient with moderately severe or severe symptomatic severe hyponatremia. A total 178 patients, who suffer from symptomatic severe hyponatremia, will be enrolled and randomly assigned to receive either intermittent bolus infusion or slow continuous infusion by 3% hypertonic saline. Subjects will take different rate of 3% hypertonic saline for 24-48 hours stratified by severity of clinical symptoms. Serum sodium will be measured at every six hours during two days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyponatremia Symptomatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intermittent bolus group

\<\<Within 6hr\>\>

* Moderately Severe : 3% saline 2ml/kg over 20min \*1 (unknown bwt 100ml)
* Severe :3% saline 2ml/kg over 20min \*2 (unknown bwt 100ml)

\<additional treatment\> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief

\<\<During 6-24hr\>\>

\- Moderately Severe or Severe

: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief

\<\<During 24-48hr\>\>

* Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief

Group Type ACTIVE_COMPARATOR

3% hypertonic saline

Intervention Type DRUG

The same as above

slow continuous infusion group

\<\<Within 24hr\>\>

\- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)

\- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)

Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)

If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na

if △ Na inc \<0.5mmol/hr or △ Na inc \<3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped

if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr

: maintain infusion rate

\<\<During 24-48hr\>\>

\- Moderately Severe and Severe

Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)

If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief

: stop 3% saline infusion regardless of △ Na

if △ Na inc \<1.5mmol/6hr

: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped

if △ Na inc ≥ 1.5mmol/6hr

: maintain infusion rate

Group Type ACTIVE_COMPARATOR

3% hypertonic saline

Intervention Type DRUG

The same as above

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3% hypertonic saline

The same as above

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* In emergency setting (2016.6-) and/or inpatients at ward (2018.9-)
* Glucose corrected serum sodium ≤125 mmol/L
* Patients with moderately severe or severe symptom

* Moderately severe

:Nausea without vomiting Drowsy, Headache General weakness, myalgia
* Severe :Vomiting, Stupor, Seizures, Coma (Glasgow Coma Scale ≤8)
* written consent

Exclusion Criteria

* Pseudohyponatremia: serum osmolality \> 275 mOsm/kg

\- If the serum osmolality is \> 275 mOsm/kg but the BUN is ≥ 30 mg/dL, the patients can be registered if calculated serum osmolality (2 x plasma \[Na\] + \[Glucose\]/18) is \<275 mOsm/kg
* Primary polydipsia: urine osmolality ≤ 100 mOsm/kg
* Glucose corrected serum sodium \>125 mmol/L
* Arterial hypotension (SBP \<90mmHg and MAP \<70mmHg)
* Anuria or urinary outlet obstruction
* Liver disease

* transaminase levels \>3 times the upper limit normal
* Known LC with ascites or diuretics use or PSE Hx or Varix Hx
* Uncontrolled diabetes mellitus (HbA1C \> 9%)
* Women who are pregnant or breast feeding
* History of cardiac surgery excluding PCA, acute myocardial infarction, sustained ventricular tachycardia, ventricular fibrillation, acute coronary syndrome, cebrovascular trauma, and increased intracranial pressure within the 3 months prior to randomization

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No